Pfizer and BioNTech have announced in a press release that their COVID-19 vaccine is highly effective in 12- to 15-year-olds. According to the release, none of the children who received the vaccine in a clinical trial developed COVID-19.
Also, they all developed strong antibody responses with no serious side effects. 2,260 participants took part in the study. Around half of the participants received the two-dose vaccine, while the other half received placebo injections. There were 18 cases of COVID-19 found in the placebo group, but none in the vaccine group contracted the virus.
This shows that the vaccine was 100 percent effective in this age group. Although the study was small, “But obviously, it looks good for the vaccine if there were zero Covid cases among the vaccinated people,” virologist Angela Rasmussen said to The New York Times.
– Apple Announces Dates For WWDC 2021, Teases Possible Device Reveal
– Hyundai Announces Halt At South Korean Plan Due To Chip Shortages
– The Best Easter Gadget Sales Ever! Pay Over Six Months With No Interest
The company says the 12- to 15-year-olds also had higher levels of antibodies one month after the second dose than people between 16 and 25 years old. Pfizer / BioNTech vaccine is authorized for people 16 years of age and older at the moment. However, with this study, the companies will seek approval from Food and Drug Administration to expand the authorization and allow the shots to be used for 12- to 15-year-olds as well.
Pfizer CEO, Albert Bourla, says the company hopes this age group can get the vaccine before the next school year. Both companies are also running a clinical trial testing the vaccine in children between six months and 11 years old.
On the other hand, Moderna is testing its COVID-19 vaccine in adolescents between 12 and 17 years old. Its also conducting trials on children between six months and 11 years old. Its current vaccine currently has approval for people 18 and older.
Johnson & Johnson, which also has a vaccine authorized for people 18 and older. It also has plans to test its one-shot immunization in younger people, from infants to 18-year-olds.
For your daily dose of tech, lifestyle, and trending content, make sure to follow Plat4om on Twitter @Plat4omLive; on Instagram @Plat4om, on LinkedIn at Plat4om, and on Facebook at Plat4om. You can also email us at email@example.com and join our channel on Telegram at Plat4om. Finally, don’t forget to subscribe to our YouTube channel HERE.